Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Nash, Denis ^a,b,c   Tymejczyk, Olga ^b   Gadisa, Tsigereda ^a   Kulkarni, Sarah Gorrell ^b   Hoffman, Susie ^a,c   Yigzaw, Muluneh ^a   Elul, Batya ^a   Remien, Robert H ^c   Lahuerta, Maria ^a   Daba, Shalo ^d   Sadr, Wafaa El ^a   Melaku, Zenebe ^a  

^a Mailman School of Public Health   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c HIV Center for Clinical and Behavioral Studies   (United States)

^d Oromia Regional State Health Bureau   (Ethiopia)

Author keywords

Antiretroviral therapy guidelines; Antiretroviral therapy initiation; Ethiopia; HIV positive adults; Implementation science; Tuberculosis treatment

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ANTIMICROBIAL THERAPY; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 T CELL COUNT TEST; COMMUNICATION DISORDER; DEMOGRAPHY; DISTRESS SYNDROME; ETHIOPIA; FEMALE; FOOD INSECURITY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL SUPPORT; STIGMA; AGED; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84973449210     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20637     Document Type: Article

References (36)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013.
2. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897908.
3. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4< B200 cells/microL) with HIV infection. HIV Med. 2004; 5(2):938.
4. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Longterm immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22(17):2291302.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2012;365(6):493505.
6. Lahuerta M, Ue F, Hoffman S, Elul B, Kulkarni SG, Wu Y, et al. The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved. 2013;24(1):35983.
7. Lahuerta M, Wu Y, Hoffman S, Elul B, Kulkarni SG, Remien RH, et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 20062011: findings from four Sub-Saharan African countries. Clin Infect Dis. 2014;58(3):43241.
8. Drain PK, Losina E, Parker G, Giddy J, Ross D, Katz JN, et al. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One. 2013;8(1):e55305.
9. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):2829.
10. Abaynew Y, Deribew A, Deribe K. Factors associated with late presentation to HIV/AIDS care in South Wollo Zone Ethiopia: a case-control study. AIDS Res Ther. 2011;8:8.
11. Zango A, Dube K, Kelbert S, Meque I, Cumbe F, Chen PL, et al. Determinants of prevalent HIV infection and late HIV diagnosis among young women with two or more sexual partners in Beira, Mozambique. PLoS One. 2013;8(5):e63427.
12. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One. 2010;5(10):e13268.
13. Hoffman S, Wu Y, Lahuerta M, Kulkarni SG, Nuwagaba-Biribonwoha H, Sadr WE, et al. Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS. 2014;28(16):242938.
14. Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, Okong P, et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc. 2011;14:46.
15. Muhamadi L, Nsabagasani X, Tumwesigye MN, Wabwire-Mangen F, Ekstrom AM, Peterson S, et al. Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD<350 cells/microL) in eastern Uganda. Health Policy. 2010;97(23):18794.
16. Central Statistical Agency [Ethiopia] and ICF International. Ethiopia Demographic and Health Survey 2011. Addis Ababa, Ethiopia: Central Statistical Agency and ICF International; 2012.
17. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO; 2013. Report No.
18. Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9(3):208.
19. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al. Short screening scales to monitor population prevalences and trends in nonspecific psychological distress. Psychol Med. 2002;32(6):95976.
20. Holzemer WL, Uys LR, Chirwa ML, Greeff M, Makoae LN, Kohi TW, et al. Validation of the HIV/AIDS Stigma Instrument - PLWA (HASI-P). AIDS Care. 2007;19(8):100212.
21. Tymejczyk O, Hoffman S, Kulkarni SG, Gadisa T, Lahuerta M, Remien RH, et al. HIV care and treatment beliefs among patients initiating antiretroviral treatment (ART) in Oromia, Ethiopia. AIDS Behav. 2015 [Epub ahead of print].
22. Rovira D, Schwefel R, Leidl J, Drummond MF. Economic aspects of AIDS and HIV infection. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 1990.
23. Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, et al. Progress, challenges, and new opportunities for the prevention of mother-tochild transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr (1999). 2012;60(Suppl 3):S7887.
24. Taha TE. Mother-to-child transmission of HIV-1 in sub-Saharan Africa: past, present and future challenges. Life Sci. 2011;88(2122):91721.
25. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49(6):61623.
26. Rosen S, Fox MP. Retention in HIV care between testing and treatment in Sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056.
27. Kohler PK, Chung MH, McGrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC. Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. AIDS. 2011;25(13):165761.
28. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):15729.
29. Del Amo J, Malin AS, Pozniak A, De Cock KM. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS. 1999;13(10):11518.
30. Vijayan T, Semitala FC, Matsiko N, Elyanu P, Namusobya J, Havlir DV, et al. Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS. Clin Infect Dis. 2013;57(12): 176672.
31. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva, Switzerland: World Health Organization; 2009.
32. Naidoo K, Baxter C, Abdool Karim SS. When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis. 2013;26(1):3542.
33. Kulkarni S, Hoffman S, Gadisa T, Melaku Z, Fantehun M, Yigzaw M, et al. Identifying perceived barriers along the HIV care continuum: findings from providers, peer educators, and observations of provider-patient interactions in ethiopia. J Int Assoc Provid AIDS Care. 2015 [Epub ahead of print].
34. Gadisa T, Tymejczyk O, Kulkarni SG, Hoffman S, Lahuerta M, Remien RH, et al. Disclosure history among persons initiating antiretroviral treatment at Six HIV clinics in Oromia, Ethiopia, 20122013. AIDS Behav. 2016 [Epub ahead of print].
35. Nash D, Wu Y, Elul B, Hoos D, El Sadr W. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS. 2011;25(12):152333.
36. Nozaki I, Kuriyama M, Manyepa P, Zyambo MK, Kakimoto K, Barnighausen T. False beliefs about ART effectiveness, side effects and the consequences of non-retention and non-adherence among ART patients in Livingstone, Zambia. AIDS Behav. 2013;17(1):1226.